Ticketplus prices IPO at $8 per share on NYSE American

Ticketplus has priced its IPO at $8 per share on the NYSE American. Simultaneously, Latigo Biotherapeutics has priced its IPO at $18 per share, aiming to raise $345.6M. Additionally, BlossomHill Therapeutics has priced its own IPO at $16 per share, targeting $150M in funding. These three companies have officially set their initial public offering prices across their respective sectors, establishing the financial terms for their upcoming market debuts and capital raises.